Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus Inc (EOLS) is a leading innovator in medical aesthetics, best known for Jeuveau, its FDA-approved botulinum toxin product for cosmetic lines. This page serves as the definitive source for verified Evolus news, providing investors and medical professionals with timely updates on corporate developments.
Access curated press releases and analysis covering regulatory milestones, financial results, and strategic partnerships. Our repository includes updates on aesthetic treatment innovations, market expansion efforts, and clinical research findings specific to Evolus' product pipeline.
Key coverage areas include quarterly earnings disclosures, manufacturing updates, physician adoption trends for Jeuveau, and international distribution agreements. All content is vetted for accuracy and relevance to stakeholders in the self-pay aesthetic sector.
Bookmark this page for efficient tracking of Evolus' performance in the competitive medical beauty market. Check regularly for objective reporting on operational developments and scientific advancements directly from corporate communications.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025, after U.S. market close.
Management will host a conference call and webcast at 4:30 p.m. ET the same day, including a Q&A session. Participants can join via phone at (800) 579-2543 (U.S.) or (785) 424-1789 (international), or through the live webcast on the company's Investor Relations webpage.
Evolus (NASDAQ: EOLS) has announced the granting of 30,579 restricted stock units (RSUs) to 13 newly hired non-executive employees under its 2023 Inducement Incentive Plan. The grants were approved by the company's compensation committee as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs have a grant date and vesting commencement date of April 7, 2025, with 25% vesting on each annual anniversary. The awards are contingent upon continuous employment through each vesting date and are subject to the terms of the 2023 Inducement Incentive Plan and respective agreements.
Evolus (NASDAQ: EOLS) has announced the commercial launch of Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, scheduled for April 18th. The launch includes an early experience program with over 1,000 key accounts and a national Evolus Academy webcast.
The Evolysse™ collection represents the company's second commercial aesthetics product after Jeuveau®, which has achieved over 14% U.S. market share and penetration in 50% of aesthetic clinics. The new products utilize innovative Cold-X™ technology for treating facial wrinkles and folds.
In clinical trials against Restylane®-L, both Evolysse™ products demonstrated statistical superiority at the 6-month primary endpoint. Evolysse™ Form showed significant differences throughout the 12-month study period, while Evolysse™ Smooth showed significant differences at 6 and 9 months, despite using 20% less product than Restylane®-L.
Evolus (NASDAQ: EOLS) has launched its 'Drop the F Word' campaign preceding the commercial release of Evolysse™, a new collection of injectable hyaluronic acid (HA) gels for treating moderate to severe facial wrinkles and folds. The campaign aims to eliminate the term 'filler' from aesthetic industry vocabulary, responding to consumer research indicating negative associations with unnatural, overfilled appearances.
The company introduces Cold-X™ technology, the first breakthrough in HA technology in over a decade, designed to better preserve the natural structure of the HA molecule. This innovative manufacturing process aims to deliver more natural-looking outcomes aligned with modern consumer expectations.
The initiative represents Evolus's strategic move to redefine industry terminology and advance the aesthetics experience, focusing on personalization, education, and natural-looking results.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has announced its upcoming participation in the Needham 24th Annual Virtual Healthcare Conference.
The company's management team will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 12:45 PM ET on Track 1, alongside investor meetings. Interested parties can access the fireside chat through the Investor Relations section of the Evolus website, with the webcast replay remaining available for 90 days following the presentation.
Evolus (NASDAQ: EOLS) has announced the issuance of inducement grants to newly hired employees. The company's compensation committee approved the grant of 29,763 restricted stock units (RSUs) to 14 non-executive employees under the Evolus' 2023 Inducement Incentive Plan. The RSUs, which were granted in accordance with Nasdaq Listing Rule 5635(c)(4), will begin vesting on March 7, 2025, with 25% vesting annually over four years. The grants are contingent upon continuous employment through each vesting date and are subject to the terms and conditions of both the incentive plan and the respective RSU agreements.
Evolus (NASDAQ: EOLS) reported strong financial results for Q4 and full-year 2024, with record global net revenue of $79.0M in Q4 (+30% YoY) and $266.3M for FY2024 (+32% YoY). The company achieved profitability ahead of schedule, posting Q4 non-GAAP operating income of $6.7M and full-year non-GAAP operating income of $0.3M.
Key highlights include:
- FDA approval of Evolysse™ in February for dynamic facial lines
- Over 15,300 total accounts with 70% reorder rate
- Evolus Rewards program grew 40% to 1.1M consumers
- Cash position of $87.0M as of December 31, 2024
For 2025, Evolus projects revenue of $345-355M (+30-33% growth), with Evolysse™ and Estyme® expected to contribute 8-10% of total revenue. The company aims to reach $700M in revenue by 2028 with non-GAAP operating margins of at least 20%.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has announced its upcoming participation in two major investor conferences in Miami, FL.
The company's management team will engage in fireside chats and investor meetings at:
- The Leerink Partners Global Biopharma Conference - Tuesday, March 11, 2025, at 9:20 AM ET
- The Barclays 27th Annual Global Healthcare Conference - Wednesday, March 12, 2025, at 3:30 PM ET
Both fireside chats will be accessible through the Investor Relations page on Evolus's website, with webcasts remaining available for 90 days following each presentation.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio, has announced its participation in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City. The event will feature a fireside chat with David Moatazedi, President and CEO of Evolus, scheduled for Thursday, February 27, 2025, from 9:30 AM to 10:00 AM ET.
The fireside chat will be accessible via live webcast on the Investor Relations page of the Evolus website, with replay availability extending 90 days after the event.
Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has scheduled its fourth quarter and year end 2024 financial results announcement for Tuesday, March 4, 2025, after U.S. financial markets close.
The company will host a conference call and live webcast at 4:30 p.m. ET on the same day, featuring management presentations followed by a question-and-answer session. Participants can join via phone by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or through the live webcast on Evolus's Investor Relations webpage.
After the call, a replay will be available by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) using conference number 13751816. An archived webcast will also be accessible on the company's website.